Back to Search
Start Over
Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2014 Nov; Vol. 58 (11), pp. 6717-23. Date of Electronic Publication: 2014 Aug 25. - Publication Year :
- 2014
-
Abstract
- Gene expression studies of subcutaneous adipose tissue may help to better understand the mechanisms behind body fat changes in HIV-infected patients who initiate antiretroviral therapy (ART). Here, we evaluated early changes in adipose tissue gene expression and their relationship to fat changes in ART-naive HIV-infected patients randomly assigned to initiate therapy with emtricitabine/tenofovir plus efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r). Patients had abdominal subcutaneous adipose tissue biopsies at baseline and week 16 and dual-energy-X-ray absorptiometry at baseline and weeks 16 and 48. mRNA changes of 11 genes involved in adipogenesis, lipid and glucose metabolism, mitochondrial energy, and inflammation were assessed through reverse transcription-quantitative PCR (RT-qPCR). Additionally, correlations between gene expression changes and fat changes were evaluated. Fat increased preferentially in the trunk with EFV and in the limbs with LPV/r (P < 0.05). After 16 weeks of exposure to the drug regimen, transcripts of CEBP/A, ADIPOQ, GLUT4, LPL, and COXIV were significantly down-regulated in the EFV arm compared to the LPV/r arm (P < 0.05). Significant correlations were observed between LPL expression change and trunk fat change at week 16 in both arms and between CEBP/A or COXIV change and trunk fat change at the same time point only in the EFV arm and not in the LPV/r arm. When combined with emtricitabine/tenofovir as standard backbone therapy, EFV and LPV/r induced differential early expression of genes involved in adipogenesis and energy metabolism. Moreover, these mRNA expression changes correlated with trunk fat change in the EFV arm. (This was a substudy of a randomized clinical trial [LIPOTAR study] registered at ClinicalTrials.gov under identifier NCT00759070.).<br /> (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Subjects :
- Acquired Immunodeficiency Syndrome drug therapy
Acquired Immunodeficiency Syndrome virology
Adenine analogs & derivatives
Adenine therapeutic use
Adiponectin biosynthesis
Adult
Alkynes
Anti-HIV Agents therapeutic use
CCAAT-Enhancer-Binding Proteins biosynthesis
Cyclopropanes
Deoxycytidine analogs & derivatives
Deoxycytidine therapeutic use
Drug Combinations
Emtricitabine
Energy Metabolism genetics
Female
Gene Expression
Glucose metabolism
Glucose Transporter Type 4 biosynthesis
HIV-1 drug effects
Humans
Inflammation genetics
Lipid Metabolism genetics
Lipoprotein Lipase genetics
Male
Organophosphonates therapeutic use
Reverse Transcriptase Inhibitors therapeutic use
Tenofovir
Adipogenesis genetics
Benzoxazines therapeutic use
Body Composition drug effects
Lopinavir therapeutic use
Ritonavir therapeutic use
Subcutaneous Fat cytology
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 58
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 25155608
- Full Text :
- https://doi.org/10.1128/AAC.03481-14